FREE CPD WEBINAR + Q&A
Closing Practice Gaps: Improving T2D Outcomes in General Practice
A case-based session on treatment intensification in T2D - part of a broader program with supporting CPD Shorts and an impactful patient identification activity.
Wednesday 11 November 2026
7:30-9:00pm (ACT, NSW, TAS, VIC)
7:00-8:30pm (SA)
6:30-8:00pm (QLD)
6:00-7:30pm (NT)
4:30-6:00pm (WA)
Event Countdown
Part of a broader program to extend your learning and your clinic's impact in Type 2 Diabetes
A case-based session on treatment intensification in T2D. Including an expert panel Q&A.
Seven short-form activities providing practical, case-based guidance to help GPs close practice gaps by applying Australian T2D recommendations for routine practice.
Identify and recall clearly defined at-risk patient cohorts with our patient identification activity (earn Measuring Outcomes hours) - with guidance from a dedicated Nurse Educator from the Wellness Clinical Services Registered Nurse team.
About this education
In this webinar, an expert multidisciplinary panel will apply Australian T2D guidance to a framework for identifying and managing patients with T2D who can benefit from clinical review or treatment intensification, from newly diagnosed patients requiring early, individualised management through to those with persistent above-target glycaemia despite established treatment.¹⁻² Through four patient cases, the panel will explore individualised HbA1c targets, early risk-factor management, therapeutic inertia, treatment initiation and intensification, the role of SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), cardiorenal risk, monitoring, and recall.¹⁻²
The webinar features a live Q&A which will allow participants to ask their challenging clinical cases and conundrums. Supported by the expert panel, participants will work through clinical scenarios and receive practical actions that can be applied in comprehensive general practice.
Learning Outcomes
Upon completion of this education you will be able to:
1
Apply individualised glycaemic targets and risk assessment to identify patients with T2D requiring treatment initiation or intensification, recognising therapeutic inertia.
2
Select glucose-lowering therapy according to patient characteristics - glycaemic requirements, cardiovascular disease, chronic kidney disease, heart failure, weight and hypoglycaemia risk.
3
Apply current Australian guidelines and PBS requirements when selecting therapy, including SGLT2 inhibitors and GLP-1 receptor agonists.
4
Implement monitoring, recall and reassessment strategies for patients with T2D who are overdue for review.
Steering committee
Continuing Professional Development (CPD) Details
This medical education activity has been approved for 1.5 Educational Activity hours, 5 Measuring Outcomes hours and 1 Reviewing Performance hour with:
Activity ID: 1689110
Activity ID: 2499
Activity ID: 43088
Automatic hours lodgement
RACGP and AMA/CPDHome members can now enjoy the convenience of rapid, automatic EA hours lodgement for this education. See your completed hours lodged within 24 hours.*
* Requires correct membership details.
Update yours now >
Please note that any additional reading or learning connected to this activity can be self recorded with your CPD body.
Praxhub is an accredited Major Provider under the RACGP CPD Program.
Praxhub is a Certified Learning Provider under the AMA's CPDHome CPD Program.
Related CPD Shorts
Quick, highly focused accredited CPD activities on osteoporosis you can finish in 30 minutes or less. Each comprises a quick video, accompanied by a short Reviewing Performance questionnaire. Earn CPD without blocking out your day. CPD lodged with RACGP automatically within 24 hours.
This series of six short-form activities provide practical, case-based guidance to help GPs close practice gaps by applying Australian T2D recommendations for routine practice. The activities address above-target HbA1c and therapeutic inertia, individualised treatment selection, SGLT2is and GLP-1 RAs treatment pathways, monitoring and recall, and shared decision-making with patients, and practical counselling when initiating a GLP-1 RA.
Pick and choose your topics and learn in any order you like.
?? mins
HbA1c can be used to diagnose diabetes, but a single result in someone without symptoms isn't enough to confirm it. The presenters walk through the risk factors to ask about, including family history, exercise, comorbidities, medications that can raise blood glucose, and the frequency of testing based on their HbA1c target levels.
?? mins
Several factors shape the choice of glucose-lowering treatment, including patient characteristics and comorbidities such as chronic kidney disease or heart disease. Learn how to weigh these factors and how to apply the patient-centred prescribing algorithm.
?? mins
This video explains how to navigate PBS criteria for GLP-1 RAs when first-line therapy is insufficient. It covers what to review when HbA1c remains above target on an SGLT2 inhibitor, the case for starting combination therapy early, and the PBS rules for switching between or combining these agents.
?? mins
Learn about the value of explaining prevention to patients, building planned care around a care plan, and using the practice database to identify and recall patients who are overdue for an HbA1c.
?? mins
An endocrinologist and a GP share practical strategies to help patients stay on their medications. They discuss collaborating with pharmacists and using My Health Record to identify missed repeats and address the reasons for them.
?? mins
Patients who know what to expect from a GLP-1 RA are more likely to keep taking it. Learn how to prepare patients for treatment, manage gastrointestinal side effects and decide when to hold off on up-titration if nausea persists.
?? mins
Should older patients with type 2 diabetes who already use insulin be considered for a GLP-1 RA? This video compares the two approaches, including hypoglycaemia risk, weight and injection frequency.
Praxhub acknowledges Novo Nordisk for its support of this education. The sponsor has provided no input into the content of this education.
References:
-
RACGP. Management of type 2 diabetes: A handbook for general practice. 2026.
-
Australian Diabetes Society. Australian Type 2 Diabetes Glycaemic Management Algorithm. 2026.
References:
-
RACGP. Management of type 2 diabetes: A handbook for general practice. 2026.
-
Usherwood T. Aust Prescr. 2024;47(1):15.
-
Wood SJ, Magliano DJ, et al. Diabet Med. 2020;37(8):1367–1373.
-
Australian Diabetes Society. Australian Type 2 Diabetes Glycaemic Management Algorithm. 2026.
-
Australian guideline and calculator for assessing and managing cardiovascular disease risk. Australian CVD Risk Guideline. 2026.
-
Imai C, Li L, Hardie RA, et al. BMJ Qual Saf. 2021;30(9):706–714.
-
Rasalam R, Abdo S, Deed G, et al. Diabetes Obes Metab. 2023;25(4):901–915.
AU26DI00072